STOX2

Across TCGA pan-cancer cohorts, STOX2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated STOX2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher STOX2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated STOX2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD and GBM are the cancer types where STOX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.924	0.351	.002	22	view →
GBM	DFS	Quartile	All	0.881	0.772	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

STOX2–LUAD (OS)

Open the LUAD breakdown →